Your browser doesn't support javascript.
loading
A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors.
Liu, Jun-Chen; Yu, Hong-Jing.
Afiliação
  • Liu JC; Department of Clinical Pharmacy, The First People's Hospital of Jiande, Jiande, People's Republic of China.
  • Yu HJ; Department of Clinical Pharmacy, The First People's Hospital of Jiande, Jiande, People's Republic of China.
Pharmgenomics Pers Med ; 16: 29-36, 2023.
Article em En | MEDLINE | ID: mdl-36714524
Immune checkpoint inhibitors (ICIs) have been shown to be significant in improving the overall survival rate in certain malignancies with poor prognoses. However, only 20-40% of patients achieve long-term benefits, highlighting the relevance of the factors that influence the treatment, which can help clinicians improve their results and guide the development of new immune checkpoint therapies. In this study, the current pharmacokinetic aspects associated with the ICIs and the factors influencing clinical efficacy were characterised, including in terms of drug metabolism, drug clearance, hormonal effects and immunosuppressive effects.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmgenomics Pers Med Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmgenomics Pers Med Ano de publicação: 2023 Tipo de documento: Article